|Bid||0.6950 x 1800|
|Ask||0.7100 x 3200|
|Day's Range||0.7000 - 0.7545|
|52 Week Range||0.4300 - 1.7400|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 17, 2020 - Aug 21, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 2:20 PM EDT.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Denis Drygin, Ph.D., as Chief Scientific Officer effective August 3, 2020.